Xtant Medical Holdings XTNT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Orthobiologics | $70.43M-3.4% | $72.89M0.0% | $72.89M+0.8% | $72.32M+4.7% | $69.08M+4.0% | |
| Spinal Implant | $36.38M-14.0% | $42.31M-5.2% | $44.61M-1.6% | $45.35M-5.7% | $48.1M-2.5% | |
| Revenue by Geography | ||||||
| Non Us | $8.87M-22.7% | $11.48M-2.3% | $11.76M+3.1% | $11.41M— | —— | |
| US | $113.04M-7.7% | $122.45M+0.9% | $121.33M+4.3% | $116.36M+5.3% | $110.5M+4.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Xtant Medical Holdings break its business down?
- Xtant Medical Holdings (XTNT) reports revenue by product across 2 parts — Orthobiologics and Spinal Implant. Each is extracted from the segment footnotes and tracked over time.
- Where does Xtant Medical Holdings's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Xtant Medical Holdings's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
